An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer

NCT01658878 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

657

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

BIOLOGICAL: Nivolumab
DRUG: Sorafenib
DRUG: Ipilimumab
DRUG: Cabozantinib

Sponsor

Bristol-Myers Squibb

Collaborators

[object Object]